论文部分内容阅读
目的探讨肺动脉高压患者药物靶向治疗的效果与耐受性。方法回顾分析2008年1月2009年8月期间8例肺动脉高压患者分别接受波生坦及西地那非治疗的临床资料,评估其临床表现、WHO肺动脉高压功能分级、6min步行距离及肺动脉收缩压在基线及治疗3个月后的变化。结果治疗后3个月,患者均能耐受药物治疗,无严重不良反应发生。WHO肺动脉高压功能分级在治疗前平均(3.1±0.4),治疗后为(2.3±0.9),明显得到改善(P<0.05)。肺动脉收缩压在治疗前平均(69.5±11.2)mmHg(1mmHg=0.133kPa),治疗后为(48.3±12.4)mmHg,明显降低(P<0.05)。6min步行距离在治疗前平均(324±48)m,治疗后为(400±43)m,明显延长(P<0.05)。结论肺动脉高压患者药物靶向治疗的疗效显著,且耐受良好。
Objective To investigate the efficacy and tolerability of drug-targeted therapy in patients with pulmonary hypertension. Methods The clinical data of 8 patients with pulmonary hypertension received bosentan and sildenafil during the period from January 2008 to August 2009 were retrospectively analyzed. The clinical manifestations, WHO classification of pulmonary hypertension, walking distance 6 min and pulmonary systolic pressure Changes at baseline and after 3 months of treatment. Results 3 months after treatment, patients were able to tolerate drug treatment, no serious adverse reactions occurred. WHO classification of pulmonary hypertension before treatment was (3.1 ± 0.4), after treatment (2.3 ± 0.9), significantly improved (P <0.05). The pulmonary systolic pressure was (69.5 ± 11.2) mmHg (1mmHg = 0.133kPa) before treatment and (48.3 ± 12.4) mmHg after treatment, which was significantly lower than that before treatment (P <0.05). The walking distance in 6min was (324 ± 48) m before treatment and (400 ± 43) m in treatment group, which was significantly prolonged (P <0.05). Conclusion The efficacy of drug-targeted therapy in pulmonary hypertension patients is significant and well tolerated.